NASDAQ: BiondVax Pharmaceuticals Rings The Nasdaq Stock Market Closing Bell

About this Marketsite Event

BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a pharmaceutical company dedicated to the development of a Universal Flu Vaccine, covering all human strains and providing protection for both seasonal and pandemic flu strains, will visit the Nasdaq MarketSite in Times Square.In honor of the occasion, Dr. Ron Babecoff, Chief Executive Officer rang the Closing Bell.BiondVax Pharmaceuticals, a publicly-traded company (TASE:BNDX) (Nasdaq:BVXV) located in the Weizmann Science Park in Ness-Ziona (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the company's Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone, a blockbuster drug for the treatment of multiple sclerosis.

Media from the Event

Photos and videos have been posted on BiondVax's website: photos | videos.

Read more on Nasdaq's website: http://www.nasdaq.com/marketsite/marketsite-events-detail.aspx?fn=201507-close07102015.txt#3#ixzz3flXTN6BE

BiondVax to Ring Closing Bell and Close Market Trading on NASDAQ on July 10, 2015

BiondVax launches a new investor relations website providing international investors with comprehensive information about the Company, progress and its strategy

Ness Ziona, Israel – July 2, 2015 – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program. This event will be the culmination of a week of meetings as part of a non-deal roadshow with US-based institutional investors and financial analysts.In addition, BiondVax today announced the launch of its new investor relations website, which can be found at www.biondvax.com.Institutional investors or analysts interested in meeting with BiondVax management in New York or wishing to attend the market closing event should contact the Company’s investor relations team.Ron Babecoff, BiondVax’s President and CEO, commented, “We are very much looking forward to launching our investor relations operations in the US. The closing event at the NASDAQ is an excellent starting point and the culmination of a long and an important process for us, of listing our shares in the United States, and by that making ourselves accessible to the US capital market.”

BiondVax Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option

Ness Ziona, Israel, June 24, 2015 – BiondVax Pharmaceuticals Ltd. (TASE: BVXV, Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters. The underwriters purchased 110,000 additional American Depositary Shares (ADSs) at a public offering price of $5.00 per ADS, whereby each ADS represents 40 of BiondVax’s ordinary shares, bringing aggregategross proceeds from the offering to $10,120,380, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BiondVax. The closing with respect to these over-allotment option shares was consummated on June 24, 2015.Aegis Capital Corp. acted as the sole book-running manager for the offering.A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission on May 11, 2015.A prospectus relating to the offering has been filed with the SEC and is available on the SEC’s web site at http://www.sec.gov.  Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website.

Biondvax Files Registration Statement

The Company hereby announces that on December 29, 2014, the Company filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed offering of American Depositary Shares in the United States. The timing of the offering, the number of shares to be offered and the price range for the proposed offering have not yet been determined.A registration statement related to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective, and there is no guarantee that this submission of such registration statement will result in the completion of the proposed offering. The registration statement can be accessed through the SEC’s website at www.sec.gov.This immediate report does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.